ADVISORY, May 23, 2014 (GLOBE NEWSWIRE) --
NPS Pharmaceuticals, Inc. (Nasdaq:NPSP), a global biopharmaceutical company pioneering and delivering innovative therapies that transform the lives of patients with rare diseases, will visit the NASDAQ MarketSite in Times Square to commemorate the 20th anniversary of the company's initial public offering and listing on the NASDAQ.
In honor of the occasion, Dr. Francois Nader, President and CEO, will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Tuesday, May 27, 2014 – 9:15 a.m. to 9:30 a.m. ET
NPS Pharma Contacts:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/
A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About NPS Pharma (Nasdaq:NPSP)
NPS Pharma is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases. The company's lead product, Gattex® (teduglutide [rDNA origin]) for injection is approved in the U.S. for adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. In the EU, teduglutide (trade name: Revestive®) is approved for the treatment of adult patients with SBS; patients should be stable following a period of intestinal adaptation after surgery. Teduglutide is not approved for the treatment of pediatric SBS patients. The safety and efficacy of teduglutide in this population is currently being evaluated in a global registration trial.
A Biologics License Application is undergoing FDA review for Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone. The Prescription Drug User Fee Act goal date for the Natpara application is October 24, 2014.
NPS Pharma's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium sensing receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin.
About NASDAQ OMX Group
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
The NASDAQ OMX Group, Inc.
New York, New York, UNITED STATES
The NASDAQ OMX Group, Inc.